Results 211 to 220 of about 94,325 (274)

Thyrotropin and IgG from patients with Graves' disease induce class-II antigen on human thyroid cells [PDF]

, 1986
Drexhage, H. A., Gutekunst, R., Mansky, T., Schultek, T., Scriba, Peter Christian, Wenzel, B. E.   +5 more
core  

Light Discomfort Thresholds in Patients with Moderate-to-Severe Active versus Mild Non-Active Thyroid Eye Disease. [PDF]

Clin Ophthalmol
Lixi F, Corrias S, Coco G, Lai R, Corda C, Cuccu A, Vitiello L, Troisi M, Mura C, Boi F, Lanzolla G, Giannaccare G.   +11 more
europepmc   +1 more source

Chronic Idiopathic Recurrent Orbital Myositis in a Patient With Concomitant Late-Onset Hashimoto's Thyroid Eye Disease. [PDF]

Cureus
Bhardwaj P, Chierigo A, Mason A, Al-Mrayat M, Lorenzano D.   +4 more
europepmc   +1 more source

Quantitative Magnetic Resonance Imaging Biomarkers in the Evaluation of Disease Activity in Thyroid Eye Disease: A Retrospective Study. [PDF]

Cureus
Marston D, Grech S, Paris AN, Galdes N, Bertuello I, Palmier A.   +5 more
europepmc   +1 more source

Advancing the Therapeutic Frontier in Thyroid Eye Disease. [PDF]

touchREV Endocrinol
Mohammadi SO, Ray C.
europepmc   +1 more source

Multimodal MRI radiomics-clinical fusion model predicts intravenous glucocorticoid response in thyroid eye disease. [PDF]

Front Endocrinol (Lausanne)
Zhou Y, Jia F, Zhao X, Ma X, Chang T, Yao S, Che K, Zhang J.   +7 more
europepmc   +1 more source

Predicting dysthyroid optic neuropathy in moderate-to-severe thyroid eye disease: a clinically applicable nomogram. [PDF]

Eur Thyroid J
Hu R, Tang S, Liu X, Liu Z, Cui Z, Chen J, Wang Y, Jiang F, Zhu J, Wan C, Sun Y, Shi L, Wang Z, Li C, Yu X, Wang C, Wang W, Lai Y, Cao Y, Wang X, Li Y, Shan Z, Teng W.   +22 more
europepmc   +1 more source

Mitigating the risks: addressing smoking cessation in thyroid eye disease. [PDF]

BMJ Open Ophthalmol
Karimi N, Kashkouli MB, Keyhani A, Aghili S, Ghahvehchian H, Askari S, Akbarian S.   +6 more
europepmc   +1 more source

Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease. [PDF]

Am J Ophthalmol Case Rep
Richkind H, Shoji MK, Routzong M, Granet D, Kikkawa DO, Rudell JC.   +5 more
europepmc   +1 more source